Searchable abstracts of presentations at key conferences in endocrinology

ea0063p301 | Reproductive Endocrinology 1 | ECE2019

After up to 11 years observation, testosterone undecanoat 1000 mg at 3 months did not increased Prostatic Specific Antigen level (January 2019)

Pisoschi Matei , Staicu Dana Cristina , Peretianu Dan , Oprisan Bogdan

Aim: Has testosterone undecanoat 1000 mg intramuscular injection (NebidoR; Bayer), 1 at 3month, negative effect on prostate? For this purpose, we appreciate the prostatic volume (see Pisoschi, this congress) and PSA (this study) in hypogonadic patients after testosterone injection up to 11 years.Material and method: A. PSA (ng/ml) was done in Bucharest accredited laboratories.B. Patients: PSA analysis was done before tre...

ea0063p302 | Reproductive Endocrinology 1 | ECE2019

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume: Study during up to 11 years on hypogonadic patients. (January 2019)

Pisoschi Matei , Staicu Dana Cristina , Peretianu Dan , Oprisan Bogdan

Aim: Re-Analysing (study starting in 2007) the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Material-method: A. Patients: at onset 278 men with hypogonadism (median: 61 y).B. Distribution: by decade (starting with 20y); no =6, 17, 25, 70, 86, 55, 18, 1.C. TUD (NebidoR-Bayer) 1000 mg injected one/3 months i.m.D. Prostate volume (PV) apprecia...

ea0049ep838 | Clinical case reports - Pituitary/Adrenal | ECE2017

A rare association of autoimmune diabetes insipidus and hypophysitis with partial pituitary insufficiency

Matei Livia , Stefaroi Corina , Mogos Simona , Branisteanu Dumitru

We present the case of a 40 year old man presenting at first consultation an ‘idiopathic’ fast-onset and severe polyuro-polydipsic syndrome (diuresis of 10 l/24 hours, with urine osmolality of less than 50 mOsm/kg and urine gravity lower than 1001). Clinical examination showed pallor and decreased pilosity at an asthenic patient with limited lesions of vitiligo and loss of libido. Water deprivation test showed the persistence of excretion of highly diluted amounts of...

ea0032p817 | Paediatric endocrinology | ECE2013

Williams syndrome: report of a case

Coles Diana , Teleanu Raluca , Sandu Magdalena , Matei Margarita

Introduction: Williams–Beuren syndrome is a rare genetic condition with clinical manifestations that include a distinct facial appearance, cardiovascular anomalies that may be present at birth or may develop later in life, idiopathic hypercalcemia, and a characteristic neurodevelopmental and behavioral profile.Case report: We present a particular case of a 3.5 years old boy, born SGA at 39 weeks of gestation with neonatal hypoxia, diagnosed at 1.6 y...

ea0032p818 | Paediatric endocrinology | ECE2013

Case report: two patients with Di George syndrome with different diagnostic peculiarities

Coles Diana , Teleanu Raluca , Vasile Daniela , Matei Margarita

Introduction: Di George syndrome is a genetic disorder caused by deletion of chromosome 22. The main features are congenital heart defects, absence or hypoplasia of thymus (with consecutive immunodeficiency and infections), hypoparathyroidism with hypocalcaemia, gastrointestinal problems, delayed psychomotor development, craniofacial abnormalities, tendency to develop seizures and psychiatric disorders.Case report: We present the case of two patients wit...

ea0045p8 | Bone | BSPED2016

Denosumab therapy for hypercalcaemia of malignancy in a young child

Saravanamuthu Abiramy , Katugampola Harshini , Collard Grace , Matei Cristina , Peters Catherine

Introduction: Hypercalcaemia secondary to malignancy is rare in childhood. Bisphosphonates have previously been shown to be effective in managing such cases in adults, however caution must be exercised in patients with renal failure or respiratory compromise. Denosumab, a RANKL monoclonal antibody is a very potent inhibitor of osteoclasts and can induce hypocalcaemia. It is not excreted by the kidney. Limited trials in adults have shown denosumab to have greater efficacy compa...

ea0073aep607 | Reproductive and Developmental Endocrinology | ECE2021

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume. Study during up to 13 years on hypogonadic patients. (January 2021)

Peretianu Dan , Pisoschi Matei , Stanciu Mihaela , Oprisan Bogdan

AimRe-Analysing (starting 2007) the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Material-methodA. Patients: at onset 333 men with hypogonadism (median: 62 y).B. Distribution: by decade (starting with 20y->90y); no = 6, 18, 35, 80, 104, 67, 21, 2.C. TUD (Neb...

ea0073aep608 | Reproductive and Developmental Endocrinology | ECE2021

After up to 13 years observation, testosterone undecanoat 1000 mg at 3 months did not increased Prostatic Specific Antigen level. Relation with prostatic volume (January 2021)

Pisoschi Matei , Stanciu Mihaela , Peretianu Dan , Oprisan Bogdan

AimWe appreciate the effect of testosterone undecanoat 1000 mg intramuscular injection (NebidoR; Bayer) on both prostatic volume (see Peretianu, this congress) and PSA (this study) in hypogonadic patients after up to 13 years.Material and methodA. PSA (ng/ml) was done in Bucharest accredited laboratories, appreciated at 1 year. B. Prostatic volume (PV): ultrasound,...

ea0084ps2-07-66 | Graves’ Disease 1 | ETA2022

Influence of thyroperoxydase and thyroglobulin antibodies on the presentation and the evolution of medically treated graves’ disease

Matei Constantinescu Stefan , Hospel Julien , Daumerie Chantal , Alexopoulou Orsalia , Maiter Dominique , Burlacu Maria-Cristina

Introduction: Thyrotropin receptor stimulating antibodies (TRAb) are responsible for Graves’ disease (GD) manifestations. Other thyroid antibodies, namely thyroperoxidase (TPOAb) and thyroglobulin (TGAb) antibodies are highly prevalent in GD, but their roles in GD presentation and evolution are controversial.Methods: We retrospectively analysed TPOAb and TGAb levels and evolution in 88 consecutive patients with newly diagnosed GD between 2000 and 20...

ea0085p13 | Bone | BSPED2022

Atypical persistence of neuropsychiatric symptoms in adolescents with primary hyperparathyroidism post parathyroidectomy- a review of two cases

Mary Tharakan Riya , Matei Cristina , Khetriwal Babita , Chesover Alexander D , Allgrove Jeremy

Introduction: Neuropsychiatric manifestations are well recognised in patients with primary hyperparathyroidism (PHP). Abnormal calcium channel physiology has been implicated in several pain disorders. The psychopathology emerges after prolonged subclinical hypercalcemia, but there is poor correlation with symptom severity. We report the complex management of two adolescents with PHP, secondary to parathyroid adenoma (no predisposing germline mutation identified), with persiste...